These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 3110896)

  • 21. Aluminum osteopathy.
    Cournot-Witmer G
    Contrib Nephrol; 1984; 38():59-64. PubMed ID: 6713901
    [No Abstract]   [Full Text] [Related]  

  • 22. Aluminium-induced osteomalacia in severe chronic renal failure (SCRF).
    Visser WJ; Van de Vyver FL
    Clin Nephrol; 1985; 24 Suppl 1():S30-6. PubMed ID: 3915958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dialysis osteomalacia and aluminum toxicity: a form of renal osteodystrophy.
    Felsenfeld AJ
    ANNA J; 1985 Jun; 12(3):189-91. PubMed ID: 3848318
    [No Abstract]   [Full Text] [Related]  

  • 24. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 25. Bone histologic response to deferoxamine in aluminum-related bone disease.
    Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ
    Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminum: culprit or accessory in the genesis of renal osteodystrophy.
    Quarles LD; Gitelman HJ; Drezner MK
    Semin Nephrol; 1986 Mar; 6(1):90-101. PubMed ID: 3299578
    [No Abstract]   [Full Text] [Related]  

  • 27. Improved bone formation in dialysis patients after substitution of calcium carbonate for aluminum gels.
    Hercz G; Andress DL; Norris KC; Shinaberger JH; Slatopolsky EA; Sherrard DJ; Coburn JW
    Trans Assoc Am Physicians; 1987; 100():139-46. PubMed ID: 3455064
    [No Abstract]   [Full Text] [Related]  

  • 28. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition and management of aluminum intoxication in children.
    Tsuru N; Williams JL; Chan JC
    Int J Pediatr Nephrol; 1987; 8(3):177-86. PubMed ID: 3323095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 31. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 32. Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis.
    Felsenfeld AJ; Gutman RA; Llach F; Harrelson JM
    Am J Nephrol; 1982; 2(3):147-54. PubMed ID: 7180912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteomalacia associated with aluminum intoxication in a patient with chronic renal failure.
    Bauer TW; Popowniak KL; Stulberg BN; McMahon JT
    Cleve Clin Q; 1985; 52(2):271-8. PubMed ID: 4028429
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic renal failure: diagnostic measures before parathyroidectomy.
    Dahl E; Nordal KP; Halse J
    Scand J Urol Nephrol; 1994 Sep; 28(3):291-4. PubMed ID: 7817173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aluminum - related osteomalacia.
    Ott SM
    Int J Artif Organs; 1983 Jul; 6(4):173-5. PubMed ID: 6629522
    [No Abstract]   [Full Text] [Related]  

  • 36. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferoxamine and aluminum removal.
    Swartz RD
    Am J Kidney Dis; 1985 Nov; 6(5):358-64. PubMed ID: 3904429
    [No Abstract]   [Full Text] [Related]  

  • 38. Elevated bone aluminum content in dialysis patients without osteomalacia.
    McCarthy JT; Kurtz SB; McCall JT
    Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.